Wishing you all the joys of the season! 
Asia Pacific Organoids Market Forecast to 2030
Asia Pacific Organoids Market Forecast to 2030 – Regional Analysis – by Organ Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Development of Biology Disease, Pathology of infectious Disease, Regenerative Medicines, Drug Discovery and Personalized Medicine, Drug Toxicity and Efficacy Testing, and Others), Source (Pluripotent Stem Cell and Organ Specific Adult Stem Cell), and Type (Instruments, Consumables, and Services)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Focus on Drug Discovery Activities Fuel the Asia Pacific Organoids Market
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated to be 356,282. A recent survey by the Hubrecht Institute states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models.
Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ’s original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study ‘CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,’ published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids’ safety, long-term stability, and functionality.
Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.
Asia Pacific Organoids Market Overview
The Asia Pacific organoids market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. The market in the region is likely to continue to grow at the fastest rate during the forecast period owing to factors such as increasing incidences of cancer, growing demand for gene mutation and cancer research, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoids products, and increased funding for organoids research.
Asia Pacific Organoids Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Organoids Market Segmentation
The Asia Pacific organoids market is segmented into organ type, type application, source, and country.
Based on organ type, the Asia Pacific organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the Asia Pacific organoids market in 2022.
Based on type, the Asia Pacific organoids market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the Asia Pacific organoids market in 2022.
Based on application, the Asia Pacific organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the Asia Pacific organoids market in 2022.
Based on source, the Asia Pacific organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the Asia Pacific organoids market in 2022.
Based on country, the Asia Pacific organoids market is segmented into the Japan, China, Australia, India, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific organoids market in 2022.
Cellesce, Corning Inc, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific organoids market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the Asia Pacific Organoids market was valued at US$ 341.24 million in 2022 and is expected to reach US$ 1,866.32 million by 2030, registering a CAGR of 23.7% from 2022 to 2030. Growing adoption of personalized drugs and rising focus on developing alternatives for animal testing models are the critical factors attributed to the Asia Pacific Organoids market expansion.
Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years.
The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.
Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcomes.
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.
On the contrary, issues related to incorporation of organoids into existing workflows hampers the Asia Pacific organoids market.
Based on organ type, the Asia Pacific organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.1% share of Asia Pacific organoids market in 2022, amassing US$ 78.97 million. It is projected to garner US$ 424.02 million by 2030 to expand at 23.4% CAGR during 2022–2030.
Based on type, the Asia Pacific organoids market is segmented into instruments, consumables, and services. The consumables segment held 57.5% share of Asia Pacific organoids market in 2022, amassing US$ 196.05 million. It is projected to garner US$ 1,136.42 million by 2030 to expand at 24.6% CAGR during 2022–2030.
Based on application, the Asia Pacific organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.6% share of Asia Pacific organoids market in 2022, amassing US$ 100.84 million. It is projected to garner US$ 577.32 million by 2030 to expand at 24.4% CAGR during 2022–2030.
Based on source, the Asia Pacific organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.2% share of Asia Pacific organoids market in 2022, amassing US$ 246.54 million. It is projected to garner US$ 1,391.07 million by 2030 to expand at 24.1% CAGR during 2022–2030.
Based on country, the Asia Pacific organoids market has been categorized into the Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that Japan captured 36.0% share of Asia Pacific organoids market in 2022. It was assessed at US$ 122.86 million in 2022 and is likely to hit US$ 643.99 million by 2030, exhibiting a CAGR of 23.0% during 2022–2030.
Key players operating in the Asia Pacific organoids market are Cellesce, Corning Inc, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, among others.
In Aug 2021, InSphero AG announced that it is making its proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues. The plates, engineered specifically for 3D cultures of spheroids and organoids, are available via InSphero’s online R&D Solutions Store.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific organoids market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Asia Pacific Key Insights
2.2 Asia Pacific Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Organoids Market Landscape
4.1 Overview
4.2 Asia Pacific PEST Analysis
5. Asia Pacific Organoids Market – Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Increasing Demand for Tumor Modeling and Biobanking
5.1.2 Growing Adoption of Personalized Drugs
5.1.3 Rising Focus on Developing Alternatives for Animal Testing Models
5.2 Key Market Restraints:
5.2.1 Issues Related to Incorporation of Organoids into Existing Workflows
5.2.2 Dearth of Skilled Professionals
5.3 Key Market Opportunities:
5.3.1 Focus on Drug Discovery Activities
5.4 Future Trends:
5.4.1 Combining Organoid with Organ-On-A-Chip
5.5 Impact Analysis:
6. Organoids Market – Asia Pacific Market Analysis
6.1 Asia Pacific Organoids Market Revenue (US$ Mn), 2022 – 2030
7. Asia Pacific Organoids Market – Revenue and Forecast to 2030 – by Type
7.1 Overview
7.2 Asia Pacific Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
7.3 Stomach
7.3.1 Overview
7.3.2 Stomach: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Intestine
7.4.1 Overview
7.4.2 Intestine: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Liver
7.5.1 Overview
7.5.2 Liver: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Pancreas
7.6.1 Overview
7.6.2 Pancreas: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Lung
7.7.1 Overview
7.7.2 Lung: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Brain
7.8.1 Overview
7.8.2 Brain: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Kidney
7.9.1 Overview
7.9.2 Kidney: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Organoids Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Asia Pacific Organoids Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Developmental Biology
8.3.1 Overview
8.3.2 Developmental Biology: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Disease Pathology of Infectious Disease
8.4.1 Overview
8.4.2 Disease Pathology of Infectious Disease: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Regenerative Medicine
8.5.1 Overview
8.5.2 Regenerative Medicine: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Drug Toxicity and Efficacy Testing
8.6.1 Overview
8.6.2 Drug Toxicity and Efficacy Testing: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Drug Discovery and Personalized Medicine
8.7.1 Overview
8.7.2 Drug Discovery and Personalized Medicine: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Organoids Market – Revenue and Forecast to 2030 – by Source
9.1 Overview
9.2 Asia Pacific Organoids Market Revenue Share, by Source 2022 & 2030 (%)
9.3 Pluripotent Stem Cells
9.3.1 Overview
9.3.2 Pluripotent Stem Cells: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Organ-specific Adult Stem Cells
9.4.1 Overview
9.4.2 Organ-specific Adult Stem Cells: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Organoids Market – Revenue and Forecast to 2030 – by Type
10.1 Overview
10.2 Asia Pacific Organoids Market Revenue Share, by Type 2022 & 2030 (%)
10.3 Instruments
10.3.1 Overview
10.3.2 Instruments: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Consumables
10.4.1 Overview
10.4.2 Consumables: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
11. Asia Pacific Organoids Market – Country Analysis
11.1 Asia Pacific Organoids Market, Revenue and Forecast to 2030
11.1.1 Overview
11.1.2 Asia Pacific Organoids Market by Country
11.1.2.1 China
11.1.2.1.1 Overview
11.1.2.1.2 China Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.1.3 China Organoids Market, by Organ Type
11.1.2.1.4 China Organoids Market, by Application
11.1.2.1.5 China Organoids Market, by Source
11.1.2.1.6 China Organoids Market, by Type
11.1.2.2 Japan
11.1.2.2.1 Overview
11.1.2.2.2 Japan Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.2.3 Japan Organoids Market, by Organ Type
11.1.2.2.4 Japan Organoids Market, by Application
11.1.2.2.5 Japan Organoids Market, by Source
11.1.2.2.6 Japan Organoids Market, by Type
11.1.2.3 India
11.1.2.3.1 Overview
11.1.2.3.2 India Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.3.3 India Organoids Market, by Organ Type
11.1.2.3.4 India Organoids Market, by Application
11.1.2.3.5 India Organoids Market, by Source
11.1.2.3.6 India Organoids Market, by Type
11.1.2.4 Australia
11.1.2.4.1 Overview
11.1.2.4.2 Australia Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.4.3 Australia Organoids Market, by Organ Type
11.1.2.4.4 Australia Organoids Market, by Application
11.1.2.4.5 Australia Organoids Market, by Source
11.1.2.4.6 Australia Organoids Market, by Type
11.1.2.5 South Korea
11.1.2.5.1 Overview
11.1.2.5.2 South Korea Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.5.3 South Korea Organoids Market, by Organ Type
11.1.2.5.4 South Korea Organoids Market, by Application
11.1.2.5.5 South Korea Organoids Market, by Source
11.1.2.5.6 South Korea Organoids Market, by Type
11.1.2.6 Rest of Asia Pacific
11.1.2.6.1 Overview
11.1.2.6.2 Rest of Asia Pacific Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.6.3 Rest of Asia Pacific Organoids Market, by Organ Type
11.1.2.6.4 Rest of Asia Pacific Organoids Market, by Application
11.1.2.6.5 Rest of Asia Pacific Organoids Market, by Source
11.1.2.6.6 Rest of Asia Pacific Organoids Market, by Type
12. Pre & Post COVID-19 Impact
12.1 Pre & Post COVID-19 Impact
13. Asia Pacific Organoids Market Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Asia Pacific Organoids Market, Key Company Profiles
14.1 STEMCELL Technologies Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Cellesce Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Thermo Fisher Scientific Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Corning Inc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Merck KGaA
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 InSphero
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
15. Appendix
15.1 About Us
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Organoids Market Segmentation
Table 2. China Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 3. China Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 4. China Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 5. China Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 6. Japan Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 7. Japan Organoids Market Revenue And Forecast to 2030 (US$ Mn) – Application
Table 8. Japan Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 9. Japan Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 10. India Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 11. India Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 12. India Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 13. India Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 14. Australia Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 15. Australia Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 16. Australia Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 17. Australia Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 18. South Korea Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 19. South Korea Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 20. South Korea Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 21. South Korea Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 22. Rest of Asia Pacific Organoids Market Revenue and Forecast to 2030 (US$ Mn) –Organ Type
Table 23. Rest of Asia Pacific Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 24. Rest of Asia Pacific Organoids Market Revenue and Forecast to 2030 (US$ Mn) Source
Table 25. Rest of Asia Pacific Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 26. Organic Developments Done by Companies
Table 27. Inorganic Developments Done by Companies
Table 28. Glossary of Terms, Asia Pacific Organoids Market
LIST OF FIGURES
Figure 1. Asia Pacific Organoids Market Segmentation, By Country
Figure 2. Asia Pacific – PEST Analysis
Figure 3. Asia Pacific Organoids Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Asia Pacific Organoids Market Revenue (US$ Mn), 2022 – 2030
Figure 6. Asia Pacific Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
Figure 7. Stomach: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Intestine: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Liver: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Pancreas: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Lung: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Brain: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Kidney: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Asia Pacific Organoids Market Revenue Share, by Application 2022 & 2030 (%)
Figure 16. Developmental Biology: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Disease Pathology of Infectious Disease: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Regenerative Medicine: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Drug Toxicity and Efficacy Testing: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Drug Discovery and Personalized Medicine: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Others: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Asia Pacific Organoids Market Revenue Share, by Source 2022 & 2030 (%)
Figure 23. Pluripotent Stem Cells: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Organ-specific Adult Stem Cells: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific Organoids Market Revenue Share, by Type 2022 & 2030 (%)
Figure 26. Instruments: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Consumables: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Services: Asia Pacific Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Asia Pacific Organoids Market, By Country -Revenue (2022) ($Mn)
Figure 30. Asia Pacific Organoids Market, By Key Countries, 2022 And 2030 (%)
Figure 31. China Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Japan Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. India Organoids Market Revenue And Forecast to 2030 (US$ Mn)
Figure 34. Australia Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. South Korea Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Rest of Asia Pacific Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 37. Pre & Post COVID-19 Impact
Figure 38. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – Asia Pacific Organoids Market
o Cellesce
o Corning Inc
o InSphero
o Merck KGaA
o STEMCELL Technologies Inc
o Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.